July 10, 2026
Connect with our experts to explore how Paradigm can support your clinical research goals.
Published by Clinical Leader
Author: Kurt Mussina, CEO, Paradigm Clinical Research, and Co-Founder, Association of Multisite Research Corporations (AMRC)
In the final article of his three-part Clinical Leader series, Kurt Mussina explains why the governed hybrid model may offer the strongest balance of patient access, physician trust, operational control, speed, quality discipline, and scalability. The article describes how a centrally governed platform can combine the strengths of freestanding research clinics and embedded private-practice research operations while using disciplined governance to reduce the variability and execution risk that can affect less controlled models.
The article covers:
- How the governed hybrid model combines access and control
- The role of freestanding clinics, embedded private-practice operations, and disciplined investigator structures
- Why governance is essential to prevent hybrid models from becoming inconsistent or fragmented
- Key governance requirements across operating infrastructure, quality accountability, and sponsor/CRO communication
- Practical implications for site operators, physician-research firms, investors, boards, CROs, and sponsors
- An operating-model evaluation checklist for assessing site organization strength
- Why operating model is becoming a strategic differentiator in clinical research site selection and platform growth
Read the full article in Clinical Leader: https://www.clinicalleader.com/doc/why-the-governed-hybrid-site-model-is-strategically-superior
About Paradigm Clinical Research
Paradigm Clinical Research is a clinical research site organization supporting phase I–IV programs across metabolic disease, dermatology, pulmonology, neurology, psychiatry, ophthalmology, and vaccines and infectious disease. Paradigm operates wholly owned clinical trial sites with centralized governance and infrastructure designed to minimize operational variability across sites, a common challenge in multi-site clinical trials.
In collaboration with more than 40 board-certified principal investigators, the company delivers expertly conducted clinical studies and access to diverse and specialty patient populations for sponsors and CRO partners. Additional information is available at www.paradigm-research.com.